- Molecular NameOlsalazine
- SynonymOlsalazine sodium
- Weight302.242
- Drugbank_IDDB01250
- ACS_NO15722-48-2
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)4.06
- pkaN/A
- LogD (pH=7, predicted)-0.94
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.0
- LogSw (predicted, AB/LogsW2.0)0.07
- Sw (mg/ml) (predicted, ACD/Labs)0.43
- No.of HBond Donors4
- No.of HBond Acceptors8
- No.of Rotatable Bonds4
- TPSA139.78
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease such as Ulcerative Colitis.
- Absorption_value8.0
- Absorption (description)N/A
- Caco_2-6.96
- Bioavailability2.0
- Protein binding99.0
- Volume of distribution (VD)6.2 L
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmApproximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S). Olsalazine-S, in contrast to olsalazine has a half-life of 7 days. Olsalazine-S accumulates to steady state within 2 to 3 weeks.
- Half lifeOlsalazine, 0.9~1 h and the 5-aminosalicylic acid metabolite, 7 days.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe most commonly reported adverse reactions leading to treatment withdrawal were diarrhea or loose stools (olsalazine 5.9%; placebo 4.8%), abdominal pain and rash or itching (slightly more than 1% of patients receiving olsalazine).
- LD50 (rat)N/A
- LD50 (mouse)N/A